Bayer CropScience Gestione
Criteri Gestione verificati 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Simon-Thorsten Wiebusch
Amministratore delegato
₹87.5m
Compenso totale
| Percentuale dello stipendio del CEO | 82.06% |
| Mandato del CEO | 2.5yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 2.1yrs |
| Durata media del Consiglio di amministrazione | 1.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | ₹7b |
| Sep 30 2025 | n/a | n/a | ₹6b |
| Jun 30 2025 | n/a | n/a | ₹6b |
| Mar 31 2025 | ₹87m | ₹72m | ₹6b |
| Dec 31 2024 | n/a | n/a | ₹5b |
| Sep 30 2024 | n/a | n/a | ₹6b |
| Jun 30 2024 | n/a | n/a | ₹7b |
| Mar 31 2024 | ₹86m | ₹70m | ₹7b |
| Dec 31 2023 | n/a | n/a | ₹8b |
| Sep 30 2023 | n/a | n/a | ₹8b |
| Jun 30 2023 | n/a | n/a | ₹8b |
| Mar 31 2023 | ₹96m | ₹82m | ₹8b |
| Dec 31 2022 | n/a | n/a | ₹8b |
| Sep 30 2022 | n/a | n/a | ₹7b |
| Jun 30 2022 | n/a | n/a | ₹7b |
| Mar 31 2022 | ₹29m | ₹25m | ₹6b |
Compensazione vs Mercato: La retribuzione totale di Simon-Thorsten ($USD 926.31K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 502.44K ).
Compensazione vs guadagni: La retribuzione di Simon-Thorsten è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Simon-Thorsten Wiebusch (49 yo)
Mr. Simon-Thorsten Wiebusch is Vice Chairman, Managing Director and Chief Executive Officer of Bayer CropScience Limited from November 1, 2023. Mr. Wiebusch was Whole-Time Director at Bayer CropScience Lim...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Vice Chairman | 2.5yrs | ₹87.47m | Nessun dato | |
| Whole-Time Executive Director & CFO | 1.2yrs | ₹3.74m | Nessun dato | |
| Company Secretary & Compliance Officer | 1.8yrs | Nessun dato | Nessun dato | |
| Country Division Head of the Pharmaceutical Division | 2.3yrs | Nessun dato | Nessun dato | |
| Country Group Mngr of Environmental Science for India | no data | ₹2.36m | Nessun dato |
Gestione esperta: Il team dirigenziale di 506285 è considerato esperto (durata media dell'incarico 2.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Vice Chairman | 4.4yrs | ₹87.47m | Nessun dato | |
| Whole-Time Executive Director & CFO | 1.2yrs | ₹3.74m | Nessun dato | |
| Non-Executive Independent Chairman | 9.8yrs | ₹2.06m | Nessun dato | |
| Non-Executive Woman Independent Director | 1.8yrs | ₹660.00k | Nessun dato | |
| Additional Non-Executive Independent Director | less than a year | Nessun dato | Nessun dato | |
| Non-Executive Non-Independent Director | 6.7yrs | Nessun dato | Nessun dato | |
| Non-Executive Non-Independent Director | 1.2yrs | Nessun dato | Nessun dato |
Consiglio di amministrazione esperto: Il consiglio di amministrazione di 506285 non è considerato esperto (durata media del mandato 1.8 anni), il che suggerisce un nuovo consiglio.
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/09 20:26 |
| Prezzo dell'azione a fine giornata | 2026/05/08 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Bayer CropScience Limited è coperta da 26 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |